drugset / Trial / NCT02235701
Study to Investigate the Safety and Activity of Aldoxorubicin Plus Ifosfamide/Mesna in Subjects With Metastatic Soft Tissue Sarcoma
RandomizedSingle-groupOpen-labelTreatment
Summary
This is a Phase 1 open-label study to study the safety and activity of aldoxorubicin with ifosfamide/mesna in subjects with metastatic, advanced, unresectable soft tissue sarcoma.
Timeline
- Start
- 2014-09-02
- Primary completion
- 2018-05-01
- Completion
- 2018-05-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aldoxorubicin | Small molecule | 170 mg/m2 | — |
| Subject | Aldoxorubicin | Small molecule | 250 mg/m2 | — |
| Background | Ifosfamide | Small molecule | 1000 mg/m2 | Intravenous |